水素在药物发现中的最新应用:更新 (2019年至今)
Jyoti Dnyaneshwar Palkhede1, Eo-Jin Park1, Om Darlami1
1Gachon Institute of Pharmaceutical Sciences and College of Pharmacy, Gachon University, Hambakmoe-ro 191, Yeonsu-gu, Incheon 21936, Republic of Korea.
Molecules (Basel, Switzerland)
|March 14, 2026
概括
水素是多功能药物支架,在治疗癌症,神经系统疾病和传染病方面表现有前途. 混合结构和计算设计的最新进展增强了它们的治疗潜力.
科学领域:
- 药用化学 医学化学
- 药物发现 药物发现 药物发现
- 有机化学 有机化学
背景情况:
- antoins (imidazolidine-2,4-dione核心) 是药物发现中的特权支架.
- 它们具有有利的特性,如结构紧性和结能力.
- 它们的多功能性允许微调药物样分子的物理化学性质.
研究的目的:
- 审查自2019年以来基于水素的药物发现的重大进展.
- 突出不同治疗领域不断发展的应用.
- 展示新的混合支架及其治疗潜力.
主要方法:
- 对2019年以来发表的研究的文献综述.
- 在瘤学,神经学和传染病中分析丹的应用.
- 在心血管,代谢和免疫疾病中检查水素.
主要成果:
- antoins显示成功作为激酶抑制剂,雄激素受体对抗剂和金属蛋白酶抑制剂.
- 新兴的作用包括调节固醇异构酶和GSK-3β.
- 新的混合支架产生强大的抗癌和抗病毒线索.
- 通过BAY-9835和GLPG1972证明了心血管和骨关节炎疾病的临床潜力.
- 新的衍生品显示出对抗多药耐药性和被忽视的热带疾病的承诺.
结论:
- antoins及其类似物处于小分子药物发现的最前沿.
- 设计和杂交的进步提高了目标选择性和药理动力学.
- 它们为各种疾病的治疗创新提供了显著的前景.
相关概念视频
Drug Discovery: Overview
12.7K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
12.7K
Targets for Drug Action: Overview
11.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
11.0K
Pharmacogenomics: Identification of New Drug Targets
73
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
73
Structure-Activity Relationships and Drug Design
1.9K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.9K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K


